IC14 (Atibuclimab)

Atibuclimab · Implicit Bioscience

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IC14 (Atibuclimab), covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI [Phase 1, Phase 2]